Skip to main content
SpringerLink
Log in

Clinical Worsening During Long-Term Follow-Up in Inoperable Chronic Thromboembolic Pulmonary Hypertension

  • Published:
Lung Aims and scope Submit manuscript

Abstract

Background

Pulmonary endarterectomy is the treatment of choice in chronic thromboembolic pulmonary hypertension (CTEPH). Modern pulmonary vasoactive medication (like endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, and prostacyclins) is used in patients with an inoperable disease and improved prognosis. We evaluate mortality and time to clinical worsening (TtCW) in inoperable CTEPH patients during long-term follow-up.

Methods

All 32 patients with inoperable CTEPH were enrolled between June 2002 and January 2009. TtCW was defined as the combination of death, need for intravenous pulmonary arterial hypertension medication, or 15% decrease in 6-minute walk distance (6-MWD) without improvement in functional class. The Cox proportional hazard regression was used to identify predictors.

Results

During a mean follow-up of 3.4 years (range = 0.2–10.2 years), 11 patients died (34%). The 1- and 3-year survival rates were 87 and 77%, respectively. Baseline functional class, 6-MWD, mean pulmonary artery pressure, and pulmonary vascular resistance were predictors for survival. Clinical worsening occurred in 16 patients (50%). The 1- and 3-year rates of freedom from clinical worsening were 74 and 60%, respectively. The only predictor for clinical worsening was the baseline 6-MWD.

Conclusion

Despite the improvement in medical treatment of inoperable CTEPH, the mortality rate is still high, and clinical worsening occurred in a substantial number of patients during a follow-up of more than 3 years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Fedullo PF, Auger WR, Kerr KM, Rubin LJ (2001) Chronic thromboembolic pulmonary hypertension. N Engl J Med 345:1465–1472

    Article  PubMed  CAS  Google Scholar 

  2. Becattini C, Agnelli G, Pesavento R, Silingardi M, Poggio R, Taliani MR, Ageno W (2006) Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest 130:172–175

    Article  PubMed  Google Scholar 

  3. Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, Albanese P, Biasiolo A, Pegoraro C, Iliceto S, Prandoni P, Thromboembolic Pulmonary Hypertension Study Group (2004) Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350:2257–2264

    Article  PubMed  CAS  Google Scholar 

  4. Riedel M, Stanek V, Widimsky J, Prerovsky I (1982) Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest 81:151–158

    Article  PubMed  CAS  Google Scholar 

  5. Klepetko W, Mayer E, Sandoval J, Trulock EP, Vachiery JL, Dartevelle P, Pepke-Zaba J, Jamieson SW, Lang I, Corris P (2004) Interventional and surgical modalities of treatment for pulmonary arterial hypertension. J Am Coll Cardiol 43:73S–80S

    Article  PubMed  Google Scholar 

  6. Auger WR, Kim NH, Kerr KM, Test VJ, Fedullo PF (2007) Chronic thromboembolic pulmonary hypertension. Clin Chest Med 28:255–269

    Article  PubMed  Google Scholar 

  7. Auger WR, Kerr KM, Kim NH, Ben-Yehuda O, Knowlton KU, Fedullo PF (2004) Chronic thromboembolic pulmonary hypertension. Cardiol Clin 22:453–466

    Article  PubMed  Google Scholar 

  8. Bonderman D, Nowotny R, Skoro-Sajer N, Jakowitsch J, Adlbrecht C, Klepetko W, Lang IM (2005) Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 128:2599–2603

    Article  PubMed  CAS  Google Scholar 

  9. Hoeper MM, Kramm T, Wilkens H, Schulze C, Schafers HJ, Welte T, Mayer E (2005) Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 128:2363–2367

    Article  PubMed  CAS  Google Scholar 

  10. Hughes RJ, Jais X, Bonderman D, Suntharalingam J, Humbert M, Lang I, Simonneau G, Pepke-Zaba J (2006) The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J 28:138–143

    Article  PubMed  CAS  Google Scholar 

  11. Hughes R, George P, Parameshwar J, Cafferty F, Dunning J, Morrell NW, Pepke-Zaba J (2005) Bosentan in inoperable chronic thromboembolic pulmonary hypertension. Thorax 60:707

    Article  PubMed  CAS  Google Scholar 

  12. Post MC, Plokker HW, Kelder JC, Snijder RJ (2009) Long-term efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension. Neth Heart J 17:329–333

    Article  PubMed  CAS  Google Scholar 

  13. Jaïs X, D’Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, Hoeper MM, Lang IM, Mayer E, Pepke-Zaba J, Perchenet L, Morganti A, Simonneau G, Rubin LJ; Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study Group (2008) Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronic Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 52:2127–2134

    Google Scholar 

  14. Seyfarth HJ, Halank M, Wilkens H, Schäfers HJ, Ewert R, Riedel M, Schuster E, Pankau H, Hammerschmidt S, Wirtz H (2010) Standard PAH therapy improves long term survival in CTEPH patients. Clin Res Cardiol 99:553–556

    Article  PubMed  CAS  Google Scholar 

  15. Reichenberger F, Voswinckel R, Enke B, Rutsch M, El Fechtali E, Schmehl T, Olschewski H, Schermuly R, Weissmann N, Ghofrani HA, Grimminger F, Mayer E, Seeger W (2007) Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J 30:922–927

    Article  PubMed  CAS  Google Scholar 

  16. Suntharalingam J, Treacy CM, Doughty NJ, Goldsmith K, Soon E, Toshner MR, Sheares KK, Hughes R, Morrell NW, Pepke-Zaba J (2008) Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest 134:229–236

    Article  PubMed  CAS  Google Scholar 

  17. Cabrol S, Souza R, Jais X, Fadel E, Ali RH, Humbert M, Dartevelle P, Simonneau G, Sitbon O (2007) Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 26:357–362

    Article  PubMed  Google Scholar 

  18. Condliffe R, Kiely DG, Gibbs JS, Corris PA, Peacock AJ, Jenkins DP, Hodgkins D, Goldsmith K, Hughes RJ, Sheares K, Tsui SS, Armstrong IJ, Torpy C, Crackett R, Carlin CM, Das C, Coghlan JG, Pepke-Zaba J (2008) Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 177:1122–1127

    Article  PubMed  Google Scholar 

  19. Bonderman D, Skoro-Sajer N, Jakowitsch J, Adlbrecht C, Dunkler D, Taghavi S, Klepetko W, Kneussl M, Lang IM (2007) Predictors of outcome in chronic thromboembolic pulmonary hypertension. Circulation 115:2153–2158

    Article  PubMed  Google Scholar 

  20. Saouti N, de Man F, Westerhof N, Boonstra A, Twisk J, Postmus PE, Vonk Noordegraaf A (2009) Predictors of mortality in inoperable chronic thromboembolic pulmonary hypertension. Respir Med 103:1013–1019

    Article  PubMed  Google Scholar 

  21. Lewczuk J, Piszko P, Jagas J, Porada A, Wójciak S, Sobkowicz B, Wrabec K (2001) Prognostic factors in medically treated patients with chronic pulmonary embolism. Chest 119:818–823

    Article  PubMed  CAS  Google Scholar 

  22. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, Nakanishi N, Miyatake K (2000) Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161:487–492

    PubMed  CAS  Google Scholar 

  23. McLaughlin VV, Badesch DB, Delcroix M, Fleming TR, Gaine SP, Galiè N, Gibbs JS, Kim NH, Oudiz RJ, Peacock A, Provencher S, Sitbon O, Tapson VF, Seeger W (2009) End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol 54:S97–S107

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors have no conflict of interests to disclose.

Author information

Authors and Affiliations

  1. Department of Cardiology, St. Antonius Hospital, Koekoekslaan 1, 3435, CM, Nieuwegein, The Netherlands

    Bastiaan E. Scholzel, Martijn C. Post & H. W. Thijs Plokker

  2. Department of Pulmonology, St. Antonius Hospital, Nieuwegein, The Netherlands

    Repke J. Snijder

Authors
  1. Bastiaan E. Scholzel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martijn C. Post
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. W. Thijs Plokker
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Repke J. Snijder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martijn C. Post.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scholzel, B.E., Post, M.C., Thijs Plokker, H.W. et al. Clinical Worsening During Long-Term Follow-Up in Inoperable Chronic Thromboembolic Pulmonary Hypertension. Lung 190, 161–167 (2012). https://doi.org/10.1007/s00408-011-9350-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00408-011-9350-z

Keywords

Search

Navigation